Literature DB >> 3017871

Recombinant human interferon gamma suppresses HTLV-III replication in vitro.

H Nakashima, T Yoshida, S Harada, N Yamamoto.   

Abstract

Effect of human interferon gamma (rINF gamma) on HTLV-III replication was evaluated quantitatively via a novel infection system using HTLV-I-carrying MT-4 cells. Treatment of HTLV-III-infected MT-4 cells with different concentrations (I-1,000 U/ml) of rINF gamma, which did not affect the growth or viability of uninfected cells, significantly blocked the appearance of immunofluorescent antigens of HTLV-III and the virus-induced cytopathic effect in a dose-dependent manner. A plaque assay was applied to measure the exact amount of viral particles released from HTLV-III-infected MT-4 cultures either untreated or treated with rINF gamma after infection. The number of plaques per dish decreased with increasing drug concentrations. About 50% and 80% of HTLV-III replication were inhibited by the addition of 100 and 1,000 U/ml of rINF gamma, respectively. The effects of INF were observed by day 5 of incubation with the chemical. However, longer treatment of cells with rINF gamma permitted a gradual increase in viral replication. Re-addition of fresh INF into cultures did not change this pattern significantly.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3017871     DOI: 10.1002/ijc.2910380320

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages.

Authors:  Arevik Mosoian; Avelino Teixeira; Anthony A High; Robert E Christian; Donald F Hunt; Jeffrey Shabanowitz; Xinyan Liu; Mary Klotman
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae.

Authors:  H Nakashima; Y Kido; N Kobayashi; Y Motoki; M Neushul; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

Review 3.  Treatment of human immunodeficiency virus infections.

Authors:  M S Hirsch; J C Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  A soluble factor induced by an extract from Pinus parviflora Sieb et Zucc can inhibit the replication of human immunodeficiency virus in vitro.

Authors:  Y Tamura; P K Lai; W G Bradley; K Konno; A Tanaka; M Nonoyama
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

5.  Activation of interferon-regulated, dsRNA-dependent enzymes by human immunodeficiency virus-1 leader RNA.

Authors:  D N SenGupta; R H Silverman
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971

6.  Inhibition of human immunodeficiency virus type 1-induced cell fusion by recombinant human interferons.

Authors:  D E Wells; S Chatterjee; M J Mulligan; R W Compans
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

Review 7.  Pathogenesis of human immunodeficiency virus infection and prospects for control.

Authors:  D D Ho; J C Kaplan
Journal:  Yale J Biol Med       Date:  1987 Nov-Dec

8.  Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro.

Authors:  R S Kornbluth; P S Oh; J R Munis; P H Cleveland; D D Richman
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

9.  Can non-lytic CD8+ T cells drive HIV-1 escape?

Authors:  Nafisa-Katrin Seich Al Basatena; Konstantinos Chatzimichalis; Frederik Graw; Simon D W Frost; Roland R Regoes; Becca Asquith
Journal:  PLoS Pathog       Date:  2013-11-14       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.